Novavax: Sanofi Partnership Revives Business and Promises Billions in Revenue

Novavax is a biotechnology company that develops vaccines for diseases. The license agreement with Sanofi aims not only to co-commercialize a Covid-19 vaccine, but more importantly to develop a new combination product for high-risk seniors. The company will be eligible for clinical milestones and royalties that could add up to billions of dollars in revenue over the coming years and decades Novavax (NASDAQ: NVAX) is a biotechnology company developing vaccines. The company is in clinical development and is focused on delivering novel...